.
MergerLinks Header Logo

Announced

ArchiMed to acquire Stragen Pharma.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Majority

Private

generic drugmaker

Pending

Pharmaceuticals

Acquisition

Switzerland

Cross Border

Single Bidder

Friendly

Private Equity

Synopsis

Edit

ArchiMed, an investment management firm, agreed to acquire Stragen Pharma, a developer of hard-to-make, complex generic drugs for the treatment of patients with life-threatening conditions. Financial terms were not disclosed. “ArchiMed knows our market inside and out. With their backing, Stragen will have the means and freedom to pursue growth," Jean-Luc Tétard, Stragen Pharma Founder and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US